Bath treatment, an alternative method for the administration of the quinolones flumequine and oxolinic acid to halibut Hippoglossus hippoglossus, and in vitro antibacterial activity of the drugs against some Vibrio sp.

O. B. Samuelsen¹,*, B. T. Lunestad²

¹Institute of Marine Research, Department of Aquaculture, Strandgaten 229, N-5024 Bergen, Norway
²Directorate of Fisheries, Department of Quality Control, Central Laboratory, Strandgaten 229, N-5002 Bergen, Norway

ABSTRACT: Administration of flumequine and oxolinic acid to halibut Hippoglossus hippoglossus by bath resulted in significant tissue levels of both the antibacterials. Bath treatment using 150 mg l⁻¹ of flumequine and 200 mg l⁻¹ of oxolinic acid for 72 h resulted in flumequine concentrations of 14.2 µg g⁻¹ in muscle and 85.4 µg g⁻¹ in abdominal organ homogenate and oxolinic acid concentrations of 9.4 µg g⁻¹ in muscle and 72.6 µg g⁻¹ in abdominal organ homogenate. Excretion of both antibacterials was rapid and characterised by elimination half-lives (t₁/₂) of 10 and 15.6 h respectively for flumequine and oxolinic acid in muscle and 9.8 and 15.0 h respectively in the abdominal organ homogenate. The corresponding elimination times (Eₜ) were 6.5 and 8 d respectively for flumequine and oxolinic acid in muscle and 7.5 and 9 d respectively in abdominal organ homogenate when a maximum residue concentration of 0.05 µg g⁻¹ was applied for both drugs. The minimum inhibitory concentration (MIC) against strains of Vibrio sp. ranged from 0.015 to 1.0 µg ml⁻¹ for flumequine and 0.015 to 0.5 µg ml⁻¹ for oxolinic acid. Following bath treatment, tissue levels of flumequine and oxolinic acid greater than MIC for susceptible strains (<0.0625 µg ml⁻¹) were maintained for up to 6.5 and 8 d respectively for flumequine and oxolinic acid in muscle and 7.5 and 9 d respectively in abdominal organ homogenate.

KEY WORDS: Halibut · Bath treatment · Quinolones · Antibacterial activity

INTRODUCTION

Flumequine (FLU) and oxolinic acid (OXA) are broad-spectrum synthetic antibacterial agents and members of the 4-quinolone series of antibacterials. Quinolones are especially active against Gram-negative bacteria and have been recommended for the treatment of urinary tract and enteric infections in humans (Wolfson & Hooper 1989). The antibacterial activity of quinolones is based on the inhibition of DNA-gyrase resulting in an unstable condensation of the DNA configuration of the bacterial DNA molecule during cell division (Wolfson & Hooper 1989). Flumequine and OXA have been used intensively to treat systemic bacterial infections such as furunculosis caused by Aeromonas salmonicida, vibriosis caused by Vibrio anguillarum and enteric redmouth disease caused by Yersinia ruckeri in fish (Michel et al. 1980, Austin et al. 1983, Rodgers & Austin 1983, Scallan & Smith 1985, O’Grady et al. 1988). The widespread use of FLU and OXA for the treatment of bacterial infections in fish is mainly due to their relatively low minimum inhibitory concentrations (MIC) for most susceptible fish pathogens (Martinsen 1993) and effective systemic distribution when adminis-
tered orally via medicated feed (Chevalier et al. 1981).

Injection into the peritoneal cavity or muscle represents the most effective and accurate means of administering a therapeutic dose of an antibacterial agent to an individual fish. However, since individual injection is costly in time and labour and causes stress to the fish it is inappropriate as a routine method of chemotherapy. At present, injection is only used in the treatment of valuable broodstock fish. Oral administration of drugs using food pellets containing the desired antibacterial substance permits treatment of large quantities of fish relatively easily at a moderate cost in labour and has become the prime route of medication. However, diseased fish often show reduced appetite, which together with hierarchical behaviour will result in uneven distribution of the antibacterial in the stock. This gives rise to a situation where only healthy individuals that are still feeding are protected by the antibacterials. Bath treatment offers an equal dose to both healthy and diseased fish and is easy to carry out with agents of sufficient water-solubility. Being restricted to tanks of limited size, bath treatment may be an alternative in treating small fish where the feed uptake is minimal due to infection, low temperature or early stages of development. It has previously been demonstrated that bath administration of erythromycin with surfactant could eliminate Aeromonas salmonicida from the intestine of fish (Roberts 1980). Bath treatment with FLU was shown to successfully eliminate stress inducible furunculosis in Atlantic salmon Salmo salar smolts (O’Grady & Smith 1992). Bath administration of sulphonamides and trimethoprim has shown the drugs to be well absorbed in both rainbow trout Oncorhynchus mykiss and cod Gadus morhua (Bergsjo 1974, Bergsjo & Bergsjo 1978, Bergsjo & Sengen 1980, Borgan et al. 1981).

Several studies have addressed the pharmacokinetics of OXA and FLU in fish held in seawater (Hustvedt & Salte 1991, Hustvedt et al. 1991, Ishida 1992, Rogstad et al. 1993, Elema et al. 1994, Martinsen & Horsberg 1995). However, information on the pharmacokinetic properties of quinolones administered by bath to halibut is not presently available in the literature.

The aim of this study was to determine the absorption, tissue distribution and elimination of FLU and OXA in halibut following bath treatment, and also the in vitro MIC values for the drugs against some strains of Vibrio sp.

**MATERIALS AND METHODS**

**Chemicals.** Flumequine (FLU) and oxolinic acid (OXA) were obtained from Norsk Medisinaldepot (Bergen, Norway). Methanol, acetonitrile, tetrahydrofuran (HPLC-grade), sodium hydroxide (NaOH) and oxalic acid dihydrate were all from Merck (Darmstadt, Germany).

**Chromatography.** The HPLC system used consisted of a Spectra-Physics SP 8800 ternary HPLC-pump (Spectra-Physics, San Jose, CA, USA) connected to a Spectra-Physics SP 8780 X R Autosampler and a Shimadzu RF-535 fluorescence detector (Shimadzu, Kyoto, Japan) operating at an excitation wavelength of 325 nm and an emission wavelength of 360 nm. The integrator was the model SP-4270 from Spectra-Physics. The HPLC system was programmed to inject 20 μl samples into the 150 × 4.6 mm analytical column packed with 3 μm particles of MGS-Hypersil (C-8), (Shandon Southern Products, Astmoor, UK) in our laboratory using a Shandon column packing machine. The column was operated at room temperature. The mobile phase used contained A: 0.025 M oxalic acid pH 3.2 - acetonitrile - methanol - tetrahydrofuran (80 - 2.5 - 15 - 2.5 v/v) and B: oxalic acid pH 3.2 - acetonitrile - methanol - tetrahydrofuran (50 - 20 - 25 - 5 v/v). The solutions were filtered through a 0.2 μm Millipore filter. The elusion profile was as follows: 0 to 4 min., 50 to 100% B linear gradient; 4 to 10 min. isotonic 100% B; 10.1 to 15 min. isotonic 50% A and 50% B. The flow rate was 1 ml min⁻¹.

Stock solutions of FLU and OXA were prepared at a concentration of 0.1 mg ml⁻¹ in 0.1 M NaOH and stored at −20°C. Working standards were prepared by dilution from the stock solutions with 0.1 M NaOH.

**Experimental fish.** Approximately 250 halibut obtained from Tinfos Aqua (Kvinesdal, Norway), ranging in weight from 3 to 5 g, were maintained in a circular (1 m × 2.5 m i.d.) flow-through seawater tank at the laboratory of the Institute of Marine Research, Bergen, Norway. The seawater had a salinity of 33% and a temperature of 12 °C ± 0.5°C. Ten fish were taken prior to initiation of the study and analysed by HPLC to confirm the absence of FLU and OXA from the tissues. Tissues from these fish also served as samples for the calibration curves.

**Bath administrations.** The bath administrations were carried out in 40 l glass aquaria containing 20 l of the drug solution. The drugs were dissolved in 50 ml of a 0.025 M solution of NaOH and added to the seawater to a final concentration of 150 mg l⁻¹ of FLU or 200 mg l⁻¹ of OXA. It was decided to use a FLU concentration of 150 mg l⁻¹ in the bath due to lethality on 1 of 5 fish in a preliminary experiment using a bath concentration of 200 mg l⁻¹. Extremely high concentrations of FLU in both muscle (136.4 μg g⁻¹) and abdominal organ homogenate (580.8 μg g⁻¹) was found in the dead fish. Administration of FLU by bath or by injection has shown to be capable of causing lethal concentrations of
The administration of quinolones by bath. The drug in Atlantic salmon smolts (Scallan 1983, O’Grady & Smith 1992). A possible link between oral administration of FLU to Atlantic salmon pre-smolts and lethality has been described by Hiney et al. (1994). The bath solutions were aerated and the aquaria equipped with a filter-pump to remove fecal particles. Twenty-four hours prior to initiating bath treatment the test fish were transferred to the aquaria for acclimatisation. The fish were kept in the drug solution for 72 h followed by transfer of the remaining fish to flow-through seawater tanks containing unmedicated seawater. Six fish were removed at 24, 48 and 72 h during treatment and at the following times post treatment: 1, 3, 5, 7, 10 and 14 d. The sampled fish were killed by a blow to the head and kept at −20°C until analysed.

**Sample preparation.** Samples of muscle and abdominal organ homogenate (0.1 g) were homogenised in 1.0 ml of 0.1 M NaOH solution containing the internal standard. Following homogenisation, 0.5 ml of the homogenate was transferred to a polypropylene tube. After centrifugation at 12 900 × g in a Biofuge 13 table-centrifuge (Heraeus Sepatech, Osterode am Harz, Germany) for 5 min. and filtration of the supernatant through an Acrodisc LC PVDF 0.45 μm syringe filter (Gelman Sciences, Ann Arbor, MI, USA) a clear supernatant was obtained, ready for analysis. The method had a detection limit of 0.05 μg g⁻¹ Flumequine was used as internal standard for the determination of OXA and vice versa. Due to the small size of the fish it was difficult to obtain individual samples of the organs. It was therefore decided to use a homogenate of the abdominal organs as one sample. The abdominal organ homogenate consisted mainly of liver, stomach and intestine.

**Data handling.** In the depletion phase, linear regression analysis were performed on logarithmically (ln) transformed tissue concentrations versus time. Elimination half lives ($t_{1/2}$) were calculated from the mono-exponential slope for the drug elimination. Values below the limit of detection were assumed to be zero and eliminated from the calculations. The corresponding elimination times ($E_t$) were calculated as the time were the regression line intercepts with a residue concentration of 0.05 μg g⁻¹ for the respective drugs. At present no official maximum residue limit (MRL) has been decided by the European Union for OXA or FLU in food products.

**Minimum inhibitory concentration (MIC) determinations.** Determination of MIC values was performed using the agar dilution method (Washington 1985). Strains were maintained on Mueller Hinton Agar (Difco) supplemented with 2% NaCl. Material from strains to be examined was transferred to 10 ml Difco Mueller Hinton Broth (Difco) supplemented with 2% NaCl and incubated for 48 h at 20°C giving a final cell density of approximately $5 \times 10^8$ cells ml⁻¹. Using a 10 μl inoculation loop, bacteria from this broth were distributed on the surface of Mueller Hinton Agar supplemented with 2% NaCl and containing FLU or OXA. The antibacterial agents were added to the agar in 2-fold dilutions from newly prepared stock solutions. The temperature of the agar on addition of the agents were 50°C. Following incubation at 20°C for 72 h the plates were examined for bacterial growth. The lowest concentration of FLU and OXA at which complete inhibition occurred was recorded as the MIC.

**Bacterial strains.** In the determination of MIC values the following bacterial strains were examined: *Vibrio anguillarum* serotype O1 (HI 11341), *V. anguillarum* serotype O2 α (HI 11347), *V. salmonicida* (HI 10448) and *V. splendidus* (1576/92). The first 2 strains are pathogenic to halibut whereas the strains of *V. salmonicida* and *V. splendidus* are non-pathogenic but were originally isolated from halibut (O. Bergh, Institute of Marine Research, Bergen, pers. comm.).

**RESULTS**

No lethality was observed during or after treatment. The mean concentration versus time profiles for FLU and OXA in muscle and abdominal organ homogenate are given in Figs. 1 & 2. Fish-to-fish variation expressed as standard deviation are given as error bars. The % standard deviation ranged from 4 to 24% and 10 to 21% respectively for FLU and OXA in muscle and from 14 to 26% and 10 to 46% respectively for...
abdominal organ homogenate. Peak concentrations for FLU and OXA following a 72 h bath treatment were 14.2 and 9.4 µg g⁻¹ respectively in muscle and 85.4 and 72.6 µg g⁻¹ respectively in abdominal organ homogenate. At Day 7 post treatment, the drug concentrations in all samples were below the detection limit of the analytical method used. The elimination half lives (t₁/₂) were calculated to be 10 and 15.6 h respectively for FLU and OXA in muscle and 9.8 and 15.0 h respectively in abdominal organ homogenate. The corresponding elimination times (Eₜ) were determined to be 6.5 and 8 d respectively in muscle and 7.5 and 9 d respectively in abdominal organ homogenate. No indications of 2-phase elimination for either of the drugs was found.

The analysis showed high concentrations of both FLU and OXA in muscle and abdominal organ homogenate of halibut. Following a 72 h bath treatment with 150 mg l⁻¹ FLU and 200 mg l⁻¹ OXA, peak concentrations of 14.2 µg g⁻¹ (FLU) and 9.4 µg g⁻¹ (OXA) in muscle and 85.4 µg g⁻¹ (FLU) and 72.6 µg g⁻¹ (OXA) in abdominal organ homogenate were obtained. These concentrations are similar or considerably higher than the concentrations achieved following oral administration of these drugs to fish held in seawater. Peak concentrations following oral administration of FLU to Atlantic salmon (25 mg kg⁻¹ d⁻¹ for 6 d) were 9 and 14 µg g⁻¹ respectively in muscle and liver (Elema et al. 1994). In a study by Rogstad et al. (1993) peak concentrations were 6.58 and 19.5 µg g⁻¹ respectively for FLU in muscle and liver of Atlantic salmon treated with a single oral dose of 25 mg kg⁻¹ fish⁻¹. The corresponding values for OXA were 5.72 and 6.83 µg g⁻¹. Ishida (1992) found peak tissue concentrations of 1.2 µg g⁻¹ in muscle and 1.8 µg g⁻¹ in liver following a single oral administration of 40 mg kg⁻¹ of OXA to rainbow trout.

DISCUSSION

The analysis showed high concentrations of both FLU and OXA in muscle and abdominal organ homogenate of halibut. Following a 72 h bath treatment with 150 mg l⁻¹ FLU and 200 mg l⁻¹ OXA, peak concentrations of 14.2 µg g⁻¹ (FLU) and 9.4 µg g⁻¹ (OXA) in muscle and 85.4 µg g⁻¹ (FLU) and 72.6 µg g⁻¹ (OXA) in abdominal organ homogenate were obtained. These concentrations are similar or consider-
The *in vitro* MIC-values for FLU and OXA against the bacterial strains tested ranged from 0.015 to 1.0 µg ml\(^{-1}\) for FLU and from 0.015 to 0.5 µg ml\(^{-1}\) for OXA (Table 1). Previous studies report MIC's of FLU and OXA against strains of *Aeromonas salmonicida*, *Vibrio salmonicida*, *V. anguillarum* and *Yersinia ruckeri* to range from 0.005 to 0.5 µg ml\(^{-1}\), and most of the strains had MIC's of <0.1 µg ml\(^{-1}\) (Barnes et al. 1990, Martinsen et al. 1992, Martinsen 1993). According to the guidelines proposed by Tsoumas et al. (1989), a bacterium is susceptible to FLU and OXA if the *in vitro* MIC is <0.0625 µg ml\(^{-1}\) and moderately susceptible when the MIC is within the range of 0.125 to 0.5 µg ml\(^{-1}\). With a MIC of ≥1.0 µg ml\(^{-1}\) a strain is classified as resistant. Using this guideline, 3 of 4 strains examined were susceptible to OXA and one was moderately susceptible whereas 2 strains were susceptible to FLU, one was moderately susceptible and one was resistant. Standard oral therapy with FLU to fish in Norway is 25 mg kg\(^{-1}\) d\(^{-1}\) for 5 to 8 d and 40 mg kg\(^{-1}\) d\(^{-1}\) for 5 to 8 d for OXA. The results from this investigation show that bath treatment using FLU and OXA at concentrations of 150 and 200 mg l\(^{-1}\) respectively for 72 h maintained muscle levels in excess of an MIC-value of 0.0625 µg ml\(^{-1}\) for at least 6.5 d for FLU and 8 d for OXA. The corresponding values were 7.5 and 9 d respectively for FLU and OXA in abdominal organ homogenate.

When a drug is added to water, there are several possible absorption routes. Absorption of drugs through the gills is assumed to be of major importance whereas absorption through the skin is of relatively little significance (Parry 1966). In seawater drugs can be absorbed via the intestine as a result of the fish drinking the surrounding medium (Motais & Garcia-Romeu 1972). Bergsjo & Bergsjo (1978) showed that the uptake of sulphadimidine and sulphanilamide in rainbow trout was higher from salt water at pH 8.0 than from fresh water at pH 8.0. This indicates a supplementary absorption from the gut. However, the absorption rate of FLU and OXA measured in this investigation is very slow compared to the absorption rate of FLU in fish held in freshwater (O'Grady et al. 1988, Hiney et al. 1995). This indicate the presence of factors inhibiting absorption in seawater. An 18 min treatment in a freshwater bath with a FLU concentration of 25 mg l\(^{-1}\) and a pH of 6.5 gave peak muscle concentrations of 14 and 18.5 µg g\(^{-1}\) in 2 groups of Atlantic salmon smolt (Hiney et al. 1995). O'Grady et al. (1988) obtained serum levels of approximately 5 µg ml\(^{-1}\) of FLU in Atlantic salmon smolts following bath treatment in a 100 mg l\(^{-1}\) freshwater solution of pH 8.0 for 30 min. In the same investigation it was shown that the absorption rate of FLU in brown trout *Salmo trutta* and Atlantic salmon smolts was highly dependent on pH and the presence of calcium ions (Ca\(^{2+}\)) in the solution. A progressive decline in uptake occurred when pH was increased from 6.5 to 8 and the Ca\(^{2+}\) level in the solution was raised from 0 to 75 mg l\(^{-1}\). At higher Ca\(^{2+}\) levels the decrease in FLU absorption was less pronounced. Recent research has also shown that the concentration of magnesium (Mg\(^{2+}\)) ions found in seawater have marked effect on both the antibacterial activity and uptake of various antibacterials by fish (Lunestad & Goksøy 1990, Barnes et al. 1995, Pursell et al. 1995). Seawater contains approximately 10 and 54 mM of Ca\(^{2+}\) and Mg\(^{2+}\) respectively for FLU and OXA absorption in seawater compared to freshwater may explain the large differences in the absorption rates obtained in this study and the studies by O'Grady et al. (1988) and Hiney et al. (1995).

Excluding the measurements of OXA in abdominal organ homogenate after 72 h, Figs. 1 & 2 show that the fish to fish variation in drug concentration is small. From plasma data obtained in a multiple dose study with oral administration of FLU to healthy Atlantic salmon much higher % standard deviations of 25 to 65% could be calculated (Elema et al. 1994). These results indicate that the fish to fish variation is smaller when a drug is added to water, there are several absorption routes. Absorption of drugs through the gills is assumed to be of major importance whereas absorption through the skin is of relatively little significance (Parry 1966). In seawater drugs can be absorbed via the intestine as a result of the fish drinking the surrounding medium (Motais & Garcia-Romeu 1972). Bergsjo & Bergsjo (1978) showed that the uptake of sulphadimidine and sulphanilamide in rainbow trout was higher from salt water at pH 8.0 than from fresh water at pH 8.0. This indicates a supplementary absorption from the gut. However, the absorption rate of FLU and OXA measured in this investigation is very slow compared to the absorption rate of FLU in fish held in freshwater (O'Grady et al. 1988, Hiney et al. 1995). This indicate the presence of factors inhibiting absorption in seawater. An 18 min treatment in a freshwater bath with a FLU concentration of 25 mg l\(^{-1}\) and a pH of 6.5 gave peak muscle concentrations of 14 and 18.5 µg g\(^{-1}\) in 2 groups of Atlantic salmon smolt (Hiney et al. 1995). O'Grady et al. (1988) obtained serum levels of approximately 5 µg ml\(^{-1}\) of FLU in Atlantic salmon smolts following bath treatment in a 100 mg l\(^{-1}\) freshwater solution of pH 8.0 for 30 min. In the same investigation it was shown that the absorption rate of FLU in brown trout *Salmo trutta* and Atlantic salmon smolts was highly dependent on pH and the presence of calcium ions (Ca\(^{2+}\)) in the solution. A progressive decline in uptake occurred when pH was increased from 6.5 to 8 and the Ca\(^{2+}\) level in the solution was raised from 0 to 75 mg l\(^{-1}\). At higher Ca\(^{2+}\) levels the decrease in FLU absorption was less pronounced. Recent research has also shown that the concentration of magnesium (Mg\(^{2+}\)) ions found in seawater have marked effect on both the antibacterial activity and uptake of various antibacterials by fish (Lunestad & Goksøy 1990, Barnes et al. 1995, Pursell et al. 1995). Seawater contains approximately 10 and 54 mM of Ca\(^{2+}\) and Mg\(^{2+}\) respectively for FLU and OXA absorption in seawater compared to freshwater may explain the large differences in the absorption rates obtained in this study and the studies by O'Grady et al. (1988) and Hiney et al. (1995).

In summary this study shows that bath treatment using FLU and OXA is an alternative to oral administration as a chemotherapeutic method in the control of bacterial infections in small halibut. Both FLU and OXA were absorbed in sufficient amounts to achieve and maintain tissue levels greater than the *in vitro* MIC values for susceptible pathogens for at least 6.5 d. Provided that oxygenation is adequate, it is possible to treat a large number of fish in a comparatively small volume of water. The procedure is simple and allows the user to dispose of and destroy the remains of the drugs in a controlled manner. Due to environmental aspects and the large amount of drug needed for the treatment, this technique is however not suitable for sea cage application. Further research is needed to evaluate the maximum size of halibut suitable for bath treatment.

CONCLUSION

In summary this study shows that bath treatment using FLU and OXA is an alternative to oral administration as a chemotherapeutic method in the control of bacterial infections in small halibut. Both FLU and OXA were absorbed in sufficient amounts to achieve and maintain tissue levels greater than the *in vitro* MIC values for susceptible pathogens for at least 6.5 d. Provided that oxygenation is adequate, it is possible to treat a large number of fish in a comparatively small volume of water. The procedure is simple and allows the user to dispose of and destroy the remains of the drugs in a controlled manner. Due to environmental aspects and the large amount of drug needed for the treatment, this technique is however not suitable for sea cage application. Further research is needed to evaluate the maximum size of halibut suitable for bath treatment.
Acknowledgements. This work was funded by the Norwegian Research Council. The technical assistance of Mrs Laila Unneld, Mr Audun Haylandtjeker and Mr Hari Rudra is highly appreciated. Thanks also to Mr Odd Magne Redseth at Intervet Norbio and Mr Yngve Torgersen at the Royal Norwegian Ministry of Agriculture, Department of Veterinary Services for providing the bacterial strains.

LITERATURE CITED


Ishida N (1992) Tissue levels of oxolinic acid after oral or intravenous administration to freshwater and seawater rainbow trout. Aquaculture 102:9-15


Martinsen B (1993) Quinolones as antimicrobial drugs in aquaculture: antimicrobial activities and pharmacokinetic properties. Dr scient thesis, Norwegian College of Veterinary Medicine, Ås


Manuscript first received. January 3, 1996
Revised version accepted. June 4, 1996

Responsible Subject Editor: D. W. Bruno, Aberdeen, United Kingdom